For details on Aimovig (Erenumab), Migraine Disease Burden & Market Size Aimovig_New_Drug_Approval
EMA Approval on 31st July, 2018 of Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. This EMA approval is applicable to all 28 European Union member states plus Iceland, Norway and Liechtenstein.
For any Feedback or suggestion mail at: email@example.com
Weblink – https://pharmastate.com